(XPH) SPDR S&P Pharmaceuticals - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US78464A7220 • Health
XPH: Pharmaceuticals, Prescription, Medicines, Vaccines, Biotechnology, Therapies
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index (S&P TMI). ‣ Company URL: http://www.spdrs.com ‣ Domicile: United States
Additional Sources for XPH ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
XPH ETF Overview
| Market Cap in USD | 162m |
| Category | Health |
| TER | 0.35% |
| IPO / Inception | 2006-06-19 |
XPH ETF Ratings
| Growth 5y | 4.48% |
| Fundamental | - |
| Dividend | 57.9% |
| Rel. Strength Industry | -73.1 |
| Analysts | - |
| Fair Price Momentum | 41.20 USD |
| Fair Price DCF | - |
XPH Dividends
| Dividend Yield 12m | 1.53% |
| Yield on Cost 5y | 1.58% |
| Annual Growth 5y | 22.61% |
| Payout Consistency | 89.9% |
XPH Growth Ratios
| Growth Correlation 3m | -81.9% |
| Growth Correlation 12m | 57% |
| Growth Correlation 5y | -18.5% |
| CAGR 5y | 0.67% |
| CAGR/Mean DD 5y | 0.04 |
| Sharpe Ratio 12m | 0.26 |
| Alpha | -14.62 |
| Beta | 0.80 |
| Volatility | 18.43% |
| Current Volume | 16.4k |
| Average Volume 20d | 36.8k |
What is the price of XPH stocks?
As of January 23, 2025, the stock is trading at USD 44.50 with a total of 16,400 shares traded.
Over the past week, the price has changed by +1.48%, over one month by +2.51%, over three months by -4.37% and over the past year by +7.29%.
As of January 23, 2025, the stock is trading at USD 44.50 with a total of 16,400 shares traded.
Over the past week, the price has changed by +1.48%, over one month by +2.51%, over three months by -4.37% and over the past year by +7.29%.
Is SPDR S&P Pharmaceuticals a good stock to buy?
Neither. Based on ValueRay Analyses, SPDR S&P Pharmaceuticals is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 4.48 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of XPH as of January 2025 is 41.20. This means that XPH is currently overvalued and has a potential downside of -7.42%.
Neither. Based on ValueRay Analyses, SPDR S&P Pharmaceuticals is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 4.48 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of XPH as of January 2025 is 41.20. This means that XPH is currently overvalued and has a potential downside of -7.42%.
Is XPH a buy, sell or hold?
SPDR S&P Pharmaceuticals has no consensus analysts rating.
SPDR S&P Pharmaceuticals has no consensus analysts rating.
What are the forecast for XPH stock price target?
According to ValueRays Forecast Model, XPH SPDR S&P Pharmaceuticals will be worth about 45.5 in January 2026. The stock is currently trading at 44.50. This means that the stock has a potential upside of +2.25%.
According to ValueRays Forecast Model, XPH SPDR S&P Pharmaceuticals will be worth about 45.5 in January 2026. The stock is currently trading at 44.50. This means that the stock has a potential upside of +2.25%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 45.5 | 2.2% |